ArticleAnnals of internal medicine2014
A simple schema for informed decision making about prostate cancer screening.
Article in Annals of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.Urology · 2016Guideline
- Article
- "Sensemaking" to Aid Shared Decision Making in Clinical Practice: A Personal Response to Information Overload and Decision Abdication.Medical decision making : an international journal of the Society for Medical Decision Making · 2024Article
- A Provider-Facing Decision Support Tool for Prostate Cancer Screening in Primary Care: A Pilot Study.Applied clinical informatics · 2024Article
- Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool.Applied clinical informatics · 2024Article
- Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review.European urology · 2021Review
- Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.Clinical proteomics · 2020Review
- Screening for Prostate Cancer.The Medical clinics of North America · 2020Review
- Appraising risk in active surveillance of localized prostate cancer.Health expectations : an international journal of public participation in health care and health policy · 2019Article
- Prostate cancer screening-when to start and how to screen?Translational andrology and urology · 2018Review
- Testing of a Tool for Prostate Cancer Screening Discussions in Primary Care.Frontiers in oncology · 2018Article
- Active Surveillance in Younger Men With Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Nature reviews. Urology · 2017Review
- An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.Urology · 2016Article
- The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2016Review
- Who and when should we screen for prostate cancer? Interviews with key opinion leaders.BMC medicine · 2015Article
- Patient Communication Preferences for Prostate Cancer Screening Discussions: A Scoping Review.Annals of family medicineArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.